Who Owns Pall Corporation?
Pall Corporation is owned by Danaher Corporation, a publicly traded American multinational conglomerate. Danaher acquired Pall Corporation in 2015 for $13.8 billion. The company is headquartered in New York, USA.
Parent Company
Danaher Corporation
Acquired
2015
Status
Publicly Traded
Headquarters
New York, USA
Who Owns Pall Corporation?
- Parent Company: Danaher Corporation
- Ownership Type: Acquired
- Acquisition Year: 2015
- Company Type: Publicly Traded
- Stock Ticker: NYSE: DHR
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Pall Corporation | Danaher Corporation | Acquired |
History of Pall Corporation
- Founded: 1946
- Founders: David B. Pall
- Acquired by Danaher Corporation: 2015
Pall Corporation was founded in 1946 by David B. Pall, a chemist and inventor, in Glen Cove, New York (later headquartered in Port Washington, New York). David Pall developed innovative filtration technologies based on his research into membrane filtration and fluid purification. The company's early products focused on filtration solutions for industrial and military applications, including hydraulic fluid filtration for aircraft.
During the 1950s and 1960s, Pall Corporation expanded its filtration technology into new markets, developing products for the aerospace, pharmaceutical, and industrial sectors. The company became known for its expertise in microfiltration, ultrafiltration, and other separation technologies that could remove particles, microorganisms, and other contaminants from liquids and gases. Pall's filtration products were used in critical applications where contamination could cause equipment failure or product quality problems.
In the 1970s and 1980s, Pall Corporation expanded significantly into life sciences applications, developing filtration solutions for biopharmaceutical manufacturing and laboratory research. The growth of the biotechnology industry created substantial demand for sterile filtration products used in the manufacture of biological drugs, including monoclonal antibodies, vaccines, and other biologics. Pall's filtration products became essential components of biopharmaceutical manufacturing processes, where sterile filtration is required to remove microorganisms and other contaminants from drug products.
Pall Corporation grew into a publicly traded company, trading on the New York Stock Exchange under the ticker PLL. By fiscal year 2014, Pall had revenues of approximately $2.8 billion and approximately 10,000 employees worldwide, with operations in the United States, Europe, Asia, and other regions. The company operated through two primary business segments: Life Sciences (serving biopharmaceutical, medical, and laboratory customers) and Industrial (serving aerospace, microelectronics, energy, and other industrial customers).
In May 2015, Danaher Corporation announced its agreement to acquire Pall Corporation for approximately $13.8 billion ($127.20 per share in cash). The acquisition was the largest in Danaher's history and significantly expanded Danaher's life sciences portfolio. Danaher's rationale for the acquisition was to add Pall's leading filtration and separation technology platform to its life sciences business, complementing Danaher's existing diagnostics and environmental solutions businesses.
The Pall acquisition closed on August 31, 2015. Following the acquisition, Danaher applied its proprietary Danaher Business System (DBS), a continuous improvement methodology based on lean manufacturing principles, to Pall's operations to improve efficiency and drive growth. Under Danaher ownership, Pall has continued to develop new filtration and separation technologies for biopharmaceutical manufacturing, laboratory research, and industrial applications.
In 2016, Danaher spun off a significant portion of its industrial businesses, including Pall's industrial filtration segment, into a new publicly traded company called Fortive Corporation. The remaining Pall life sciences filtration business was retained within Danaher's Life Sciences segment. This restructuring focused Pall's operations within Danaher on the higher-growth, higher-margin life sciences filtration market.
Pall Corporation's biopharmaceutical filtration business has benefited from the continued growth of the biologics drug market, which requires extensive filtration and purification at multiple stages of the manufacturing process. The development of new biologic drugs, including monoclonal antibodies, gene therapies, and cell therapies, has created demand for increasingly sophisticated filtration and separation technologies.
About Danaher Corporation
Danaher Corporation is an American multinational conglomerate founded in 1969, headquartered in Washington, D.C. Under CEO Rainer M. Blair, Danaher is a leading global life sciences and diagnostics innovator with $24.6 billion in 2025 revenue. The publicly traded company (NYSE: DHR) operates through three main segments: Diagnostics, Life Sciences, and Environmental and Applied Solutions, with iconic brands including Cepheid, Leica Microsystems, and Pall Corporation.
- Founded: 1969
- Headquarters: Washington, D.C., USA
- Company Type: Publicly Traded
- Stock: NYSE: DHR
- Revenue: $24.6 billion (FY2025)
- Employees: Approximately 63,000
Where Is Pall Corporation Made / Based?
- Headquarters: New York, USA
- Manufacturing / Operations: United States, Europe, Asia, Americas
Pall Corporation Sustainability & Ethics
Pall Corporation operates with a strong commitment to sustainability and ethical business practices, reflecting its position as a global leader in filtration and separation technologies. The company integrates environmental responsibility into its manufacturing processes, product development, and corporate citizenship initiatives while maintaining its focus on providing critical filtration solutions for life sciences and industrial applications.
Environmental Compliance and Filtration Technology: Pall's filtration technologies contribute to environmental sustainability by enabling cleaner industrial processes, reducing waste, and improving air and water quality. The company's products help industries meet environmental regulations and reduce their environmental impact through effective contaminant removal and fluid purification.
Life Sciences Innovation: Pall's filtration solutions support sustainable biopharmaceutical manufacturing by enabling more efficient drug production processes, reducing resource consumption, and improving product yields. The company's technologies help biopharmaceutical manufacturers achieve their sustainability goals while maintaining product quality and safety.
Quality Management and Regulatory Compliance: Pall maintains rigorous quality management systems and regulatory compliance across all operations. The company's commitment to quality helps ensure the safety and efficacy of pharmaceutical products that rely on Pall's filtration technologies, supporting public health and safety.
Global Operations and Local Engagement: Pall operates manufacturing facilities worldwide and maintains active community engagement programs at its locations. The company supports local communities through employment opportunities, educational initiatives, and partnerships with local organizations.
Industrial Sustainability: Pall's industrial filtration products support sustainable manufacturing practices by enabling equipment longevity, reducing maintenance requirements, and improving energy efficiency. The company's technologies help industrial customers reduce their environmental footprint and operational costs.
Ethical Business Practices: Pall operates with strong ethical standards in all business dealings, including transparent pricing, honest marketing, and fair competition. The company maintains compliance with all applicable laws and regulations in the countries where it operates.
Research and Development Ethics: Pall invests significantly in research and development while maintaining ethical standards for innovation. The company's R&D focuses on developing filtration solutions that address real-world challenges in sustainability, health, and industrial efficiency.
Awards & Recognition
Pall Corporation has received significant recognition for its innovation in filtration technology, contributions to life sciences, and excellence in manufacturing and quality management.
Technology Innovation Awards: Pall has been recognized for its breakthrough filtration technologies and separation solutions, particularly in biopharmaceutical manufacturing where the company's products have set industry standards for purity and performance.
Quality and Manufacturing Excellence: The company's manufacturing facilities and quality management systems have received recognition from industry organizations and customers for maintaining high standards of product quality and consistency.
Life Sciences Industry Recognition: Pall's contributions to biopharmaceutical manufacturing and laboratory research have earned recognition from pharmaceutical companies and research institutions for enabling critical processes and ensuring product safety.
Aerospace and Industrial Applications: Pall's filtration technologies for aerospace and industrial applications have received recognition for their reliability and performance in demanding environments, including contributions to major infrastructure projects.
Danaher Group Recognition: As part of Danaher's portfolio, Pall benefits from the parent company's recognition for operational excellence, continuous improvement, and leadership in science and technology.
Customer Partnership Awards: Pall has received recognition from customers for its collaborative approach to problem-solving and its commitment to developing customized filtration solutions that meet specific customer needs.
Pall Corporation Recalls & Controversies
Pall Corporation maintains a strong operational record with no major product recalls, but has faced some environmental and regulatory considerations typical of industrial manufacturing companies.
Environmental Compliance Issues: In response to environmental concerns about dioxane contamination in Michigan, Pall's Vice President of Life Sciences confirmed the company's compliance with consent judgments from the Michigan Department of Environmental Quality. The company maintained that it was in full compliance with legal frameworks for environmental cleanup.
Regulatory Compliance: Pall operates in highly regulated industries, particularly biopharmaceutical manufacturing, and must maintain compliance with FDA, EMA, and other regulatory requirements for its products used in drug manufacturing processes.
Market Competition: Pall operates in competitive filtration markets but has not been involved in significant antitrust or regulatory controversies related to market competition.
Supply Chain Management: The company maintains ethical supply chain practices and has not faced significant controversies related to supplier relationships or procurement practices.
Product Safety: Pall's filtration products are subject to rigorous safety and performance testing, particularly for applications in pharmaceutical manufacturing and aerospace, where product failure could have serious consequences.
Business Restructuring: The 2016 spin-off of Pall's industrial segment into Fortive Corporation was a normal business restructuring transaction and has not been associated with any regulatory or legal controversies.
Brands Owned by Danaher Corporation
- Cepheid - Molecular diagnostics company providing point-of-care testing and infectious dis...
- Fortive Corporation - American industrial technology company providing solutions for professional inst...
- Hach - Global water quality testing and analytical instruments provider offering compre...
- Integrated DNA Technologies - Global genomics solutions provider offering oligonucleotides, genomic tools, and...
- Leica Microsystems - German manufacturer of microscopy and scientific imaging equipment for research ...
- Linx - Global provider of industrial printing and product identification solutions offe...
- Radiometer - Global leader in acute care diagnostics providing blood gas testing, electrolyte...
- Trojan UV Systems - Global leader in ultraviolet water treatment and disinfection systems providing ...
- Videojet - Global leader in product identification and coding solutions providing inkjet, l...
Pall Corporation Ownership: Pros & Cons
Advantages
- +Danaher's acquisition of Pall Corporation for approximately $13.8 billion in August 2015 provided Pall with access to Danaher's substantial financial resources, global distribution network, and the Danaher Business System (DBS) continuous improvement methodology, which has driven operational efficiency improvements across Danaher's portfolio companies
- +Pall's leading position in biopharmaceutical filtration and separation, serving critical steps in the manufacture of monoclonal antibodies, vaccines, and other biologics, provides strong competitive moats based on validated processes, regulatory compliance, and high switching costs that protect the business from competitive displacement
- +The continued growth of the global biologics drug market, driven by the development of new monoclonal antibodies, gene therapies, cell therapies, and other biologic drugs, creates sustained demand for Pall's filtration and separation products, providing a favorable long-term demand outlook
- +Danaher's 2016 restructuring, which retained Pall's life sciences filtration business within Danaher while spinning off the industrial filtration segment into Fortive, focused Pall's operations on the higher-growth, higher-margin life sciences market, improving the strategic alignment of the business
- +Pall's global manufacturing footprint, with facilities in the United States, Europe, and Asia, supports its ability to supply filtration products to biopharmaceutical manufacturers and research institutions in more than 100 countries, providing geographic diversification and supply chain resilience
Considerations
- -The biopharmaceutical filtration market is subject to cyclical fluctuations in biopharmaceutical manufacturing activity, including periods of inventory destocking by biopharmaceutical manufacturers that can reduce demand for filtration consumables, as experienced in 2022 and 2023 when the post-COVID-19 normalization of biopharmaceutical manufacturing activity led to significant inventory corrections
- -Pall faces competition from well-resourced competitors including Merck KGaA's MilliporeSigma division and Sartorius AG, both of which have invested heavily in biopharmaceutical filtration and purification technologies and have strong market positions in key segments of the biopharmaceutical manufacturing process
- -The integration of Pall's industrial filtration segment into Fortive in 2016 reduced the breadth of Pall's product portfolio within Danaher, concentrating the business on life sciences filtration and reducing the revenue diversification that the industrial segment provided
- -Regulatory requirements for biopharmaceutical manufacturing, including FDA and EMA oversight of filtration processes used in drug manufacturing, create compliance obligations for Pall's products and require ongoing investment in regulatory affairs and quality systems
- -Danaher's acquisition of Cytiva (formerly GE Healthcare Life Sciences) in 2020 for approximately $21.4 billion created a potential internal competitive dynamic within Danaher's Life Sciences segment, as Cytiva also provides bioprocessing equipment and consumables that overlap with some of Pall's product offerings
Frequently Asked Questions About Pall Corporation
Sources & Further Reading
- Pall Corporation Official Website -
- Danaher Corporation Official Website -
- Danaher Investor Relations -
- Pall Aerospace Filtration Solutions -
- Wikipedia Pall Corporation Entry -
- Filtration Industry News -
- Biopharmaceutical Manufacturing Resources -
- Industrial Filtration Technology -
- Life Sciences Industry Reports -
- Aerospace Industry Standards -
Competitors to Pall Corporation
No direct competitors found in the same category. This could be because Pall Corporationoperates in a unique market segment or we're still building our competitor database.
Danaher Corporation Stock Information
Jobs at Danaher Corporation
Latest News About Pall Corporation
Related Articles About Pall Corporation
View more articles
Monthly M&A Roundup: April 2026 Brand Ownership Changes
Global M&A reached a record $1.3 trillion in Q1 2026, and April is continuing the momentum. McCormick is buying Unilever's food business for $45 billion. Paramount and Warner Bros. Discovery are merging. Here is every major brand ownership shift entering April 2026.
How Sony Built Its Entertainment Empire
Sony started making rice cookers and radio repair equipment in 1946. Today it owns PlayStation, Columbia Pictures, Sony Music, and the world's largest music publishing catalogue. Here is the full story.
The Story Behind the Coca-Cola Acquisition Strategy
Coke, Sprite, Fanta, Minute Maid, Powerade, Dasani, Smartwater, Costa Coffee, Fuze Tea, and over 200 more brands all share one parent. Here is how The Coca-Cola Company quietly became a total beverage company.
People Also Searched
Discover popular brands and companies in the technology category and related searches from other users.
Alpha
Sony's digital camera brand offering mirrorless and DSLR cameras with advanced imaging technology for professional and enthusiast photographers.
Beats
Audio equipment brand specializing in headphones and speakers, owned by Apple Inc.
Bravia
Sony's television brand offering LED, OLED, and advanced display technology with smart TV features for home entertainment.